Skip to main content
Fig. 2 | Alzheimer's Research & Therapy

Fig. 2

From: Combination of plasma amyloid beta(1-42/1-40) and glial fibrillary acidic protein strongly associates with cerebral amyloid pathology

Fig. 2

Boxplots of raw plasma biomarker levels for amyloid PET status (negative: -; positive: +) in function of the syndrome diagnostic groups. Statistical analysis was conducted using age and sex adjusted two-way ANOVAs evaluating the independent effects of amyloid PET status and syndrome diagnosis on the plasma biomarker levels. For plasma Abeta(1-42/1-40), PET status had a main effect (p = 0009) but not syndrome diagnosis (p = 0.192). For GFAP, both PET (p < 0.001) and syndrome diagnosis (p = 0.048) had main effects. For NfL, syndrome diagnosis (p = 0.001) but not PET status (p = 0.155) had a main effect. Plasma GFAP and plasma NfL levels were natural log transformed prior to ANOVA. Abeta, amyloid beta; GFAP, glial fibrillary acidic protein; NfL, neurofilament light; PET, positron emission tomography

Back to article page